Key Highlights

● Amgen rose on Friday, closing at $414.87 and finishing among the Dow's gainers, with no company-specific news.

● The iShares Biotechnology ETF climbed solidly as Merck, Pfizer and Gilead rose and smaller Vaccine and genomics names jumped more.

● Moderna jumped $28.00 to $225.00, its highest level since 2021, on its first official day in the Nasdaq-100.

● Amgen has medicines for bone health, cardiovascular disease, inflammation and cancer and an experimental weight-loss drug in development.

Amgen (NASDAQ:AMGN) rose on Friday, closing at $414.87 and finishing among the gainers in the Dow Jones Industrial Average, which added 423.31 points to 51,654.95. There was no company-specific news from the biotech giant. Rather, Amgen moved with a broad rally in biotechnology stocks, as the iShares Biotechnology ETF, IBB, climbed solidly during the session.

The gains were widespread. Large drugmakers including Merck (NYSE:MRK), Pfizer (NYSE:PFE) and Gilead (NASDAQ:GILD) rose, and smaller vaccine and genomics names posted far bigger jumps. Health care finished as the second-best S&P 500 sector, behind real estate.

The spark: a cancer-vaccine report

The rally followed a media report that the National Institutes of Health plans a public-private campaign, starting in December, to accelerate cancer treatment research, including vaccines. According to reports, the initial focus will be on pancreatic, liver and colorectal cancers and some childhood tumors, with the aim of replicating the speed of the effort to develop Covid-19 vaccines.

Vaccine and messenger-RNA companies reacted most strongly. Moderna (NASDAQ:MRNA) jumped $28.00 to $225.00, its highest level since 2021, on its first official day in the Nasdaq-100. Novavax (NASDAQ:NVAX), BioNTech (NASDAQ:BNTX), Arcturus Therapeutics (NASDAQ:ARCT) and Vaxcyte (NASDAQ:PCVX) surged. Genomics and synthetic-biology names such as Illumina (NASDAQ:ILMN), 10x Genomics (NASDAQ:TXG) and Twist Bioscience (NASDAQ:TWST) also rallied, along with AI-focused drug developer Recursion Pharmaceuticals (NASDAQ:RXRX).

Where Amgen fits

Amgen is one of the world's largest independent biotechnology companies, with medicines for bone health, cardiovascular disease, inflammation and cancer. Its oncology portfolio includes several cancer drugs, and it has been building a presence in obesity treatment with an experimental weight-loss drug. Amgen is not primarily a vaccine company, so its gain on Friday looked more like participation in a sector-wide bid than a direct bet on the NIH initiative.

That kind of broad move is common in biotech, where investors often buy or sell the group as a whole on news that changes sentiment toward drug research and development.

A defensive rotation

Health care has been gaining favor more broadly. Over the week, health care was one of the leading sectors alongside utilities, consumer staples and energy, while technology and industrials slipped. Consumer staples had their second-best week since 2022, according to market data.

The rotation reflects a cautious macro backdrop. The 10-year Treasury Yield held near a 24-year high, and the Federal Reserve raised rates in September for the first time since 2023. Minutes from that meeting showed officials saw another increase as likely appropriate by year-end. Consumer sentiment slipped to a five-month low of 46.3, and September payrolls rose by just 29,000.

Even so, Friday was a good day overall. The S&P 500 rose 46.18 points to 7,811.54, about 7 points below its record close, and the Nasdaq Composite added 172.83 points to 27,366.17. Gainers outnumbered losers on the Nasdaq by about 1.38 to 1. The Dow posted its biggest weekly gain since the week ended August 7.

NIH Program Details and Johnson & Johnson's Earnings Set Biotech's Next Direction

US stocks trade Monday for Columbus Day, while the Bond Market is closed. September consumer prices are due Wednesday, October 14, bank earnings run October 13 to 16, and the Fed meets October 27 to 28. Investors will watch for more detail on the NIH cancer-vaccine program, including which companies take part, ahead of its expected December start. Johnson & Johnson (NYSE:JNJ) reports on Tuesday, October 13, giving an early look at health care earnings.